Complete response for Impax's Parkinson's compound

Impax Laboratories Inc. (NASDAQ:IPXL) said FDA issued a complete response letter for an NDA for Rytary extended-release carbidopa/levodopa to treat idiopathic Parkinson's disease (PD). According to th...